AstraZeneca : H1 and Q2 2023 results presentation

H1 and Q2 2023 Results

Conference call and webcast for investors and analysts

28 July 2023

Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property-related risks to our products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events such as the COVID-19 pandemic and the Russia-Ukraine war may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

2

H1 and Q2 2023 results

Conference call agenda

CEO Opening Remarks	Pascal Soriot
Chief Executive Officer
Financial Results	Aradhana Sarin
Chief Financial Officer
Oncology	Dave Fredrickson	Susan Galbraith
EVP, Oncology Business	EVP, Oncology R&D
BioPharmaceuticals	Ruud Dobber	Mene Pangalos
EVP, BioPharmaceuticals Business	EVP, BioPharmaceuticals R&D
Rare Disease	Marc Dunoyer
Chief Executive Officer, Alexion
CEO Closing Remarks, Q&A	Pascal Soriot
Chief Executive Officer

3

CEO Opening Remarks

Pascal Soriot

C H I E F E X E C U T I V E O F F I C E R

CEO Opening Remarks

Financial Results

Oncology

BioPharmaceuticals

Rare Disease

CEO Closing Remarks

Benefitting from broad-based, diverse source of revenue

Strong commercial performance and financial execution in H1 2023

Total Revenue | +4%

Core EPS | +21%

$4.07

+16%

Ex-COVID-19

Total Revenue

H1 2022

H1 2023

H1 2022

H1 2023

Vaxzevria/COVID-19 mAbs1

Total Revenue

Broad-based, diverse source of revenue

H1 2023 | % Total Revenue by therapy area

Oncology	CVRM	R&I	V&I Other	Rare Disease
39%	24%	14%	3%	3%	17%

H1 2023 | % Total Revenue by geography

US	Emerging Markets	Europe	ERoW
41%	28%	20%	12%

Reiterating 2023 guidance: Core EPS to increase by a high single-digit to low double-digit %

5	All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
1. COVID-19 mAbs = Evusheld and AZD3152, the antibody currently in development.

CER = constant exchange rates; EPS = earnings per share; CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies; ERoW = Established Rest of World.